The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Risk stratification in MDS
Hege Garelius
• 9 Jun 2022
Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, comments on risk stratification in myelodysplastic syndromes (MDS), highlighting the importance of incorporating mutations in these classifications. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
